Detection of Toxoplasma gondii in immunodeficient subjects by gene amplification: influence of therapeutics.
Polymerase chain reaction (PCR) technology was used to detect Toxoplasma gondii DNA in 253 immunodeficient subjects, 179 of whom were infected with the human immunodeficiency virus (HIV). The incidence of toxoplasmosis was 12.3% (22/179) in the HIV-infected subjects and 2.7% (2/74) in the remainder. The sensitivity of the PCR during episodes of toxoplasmosis in HIV-infected subjects not on antiparasitic treatment was 86.6% on peripheral blood and 60% on cerebrospinal fluid (CSF), but was only 25% and 16.7%, respectively, in subjects receiving specific treatment or prophylaxis against Pneumocystis carinii. Among the HIV-seronegative population, six patients undergoing anticancer chemotherapy were PCR positive on bronchoalveolar lavage fluid but did not develop pulmonary toxoplasmosis, suggesting transient carriage.
Laboratoire de Parasitologie, Hôpital Maison Blanche, France.
F
F
Foudrinier
D
D
Aubert
D
D
Puygauthier-Toubas
C
C
Rouger
I
I
Beguinot
P
P
Halbout
P
P
Lemaire
C
C
Marx-Chemla
J M
JM
Pinon
D000818:Animals; D000977:Antiparasitic Agents / Q000627:therapeutic use; D016054:DNA, Protozoan / Q000032:analysis; D015658:HIV Infections / Q000150:complications; D006801:Humans; D016867:Immunocompromised Host; D009894:Opportunistic Infections / Q000175:diagnosis* / Q000188:drug therapy / Q000469:parasitology*; D016133:Polymerase Chain Reaction; D012680:Sensitivity and Specificity; D014122:Toxoplasma / Q000302:isolation & purification*; D014123:Toxoplasmosis / Q000150:complications / Q000175:diagnosis*
D000977:Antiparasitic Agents; D016054:DNA, Protozoan